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Radiolabeled annexin V (ANV) has been widely used for imaging cell apoptosis. Recently, a novel ANV-Kunitz-type protease
inhibitor fusion protein, ANV-6L15, was found to be a promising probe for improved apoptosis detection based on its higher
aﬃnity to phosphatidylserine (PS) compared to native ANV. The present paper investigates the feasibility of apoptosis detection
usingradioiodinatedANV-6L15.NativeANVandANV-6L15werelabeledwithiodine-123andiodine-125usingIodogenmethod.
Thebindingbetweentheradioiodinatedproteinsanderythrocyteghostsorchemical-inducedapoptoticcellswasexamined.ANV-
6L15 can be radioiodinated with high yield (40%−60%) and excellent radiochemical purity (>95%). 123I-ANV-6L15 exhibited a
higher binding ratio to erythrocyte ghosts and apoptotic cells compared to 123I-ANV. The biodistribution of 123I-ANV-6L15 in
mice was also characterized. 123I-ANV-6L15 was rapidly cleared from the blood. High uptake in the liver and the kidneys may limit
the evaluation of apoptosis in abdominal regions. Our data suggest that radiolabled ANV-6L15 may be a better scintigraphic tracer
than native ANV for apoptosis detection.
1.Introduction
Apoptosis (programmed cell death) plays an important role
in the maintenance of physiological homeostasis as well
as in the pathogenesis of a number of disorders including
cerebral and myocardial ischemia, autoimmune diseases,
and neurodegeneration [1–3]. Apoptosis also plays a crucial
role in tumor response to radiation, chemotherapy, and
photodynamictherapy(PDT)[4].Theextentandtimeframe
of cancer cell apoptosis induced by anticancer treatments
provide crucial clinical information on both the disease
status and the therapeutic eﬃcacy.
The plasma membrane phospholipids of mammalian
cells are normally asymmetrically distributed, in which
the phosphatidylserine (PS) and phosphatidylethanolamine
(PE) are segregated to the internal leaﬂet whereas the
phosphatidylcholine (PC) and sphingomyelin (SM) reside
on the outer leaﬂet [5, 6]. Once apoptosis has been initiated,
the caspase-mediated signaling cascade of cells is activated.
One of the earliest events occurred in apoptotic cells is
the externalization of PS to the outer leaﬂet of the plasma
membrane.
Annexin V (ANV), an endogenous human protein with
a molecular weight of 35.8kDa, binds to membrane-bound2 Journal of Biomedicine and Biotechnology
PS in a Ca2+-dependent manner with a high aﬃnity (Kd =
0.5–7nM). Since externalization of PS occurs in the early
stage of apoptosis, ﬂuorescein- and radionuclide-labeled
ANV have been used for detection of apoptosis in vitro
and under development for in vivo imaging as well [3, 7].
However, the physiological concentration of Ca2+ is lower
than that required for optimal binding of native ANV to PS
[8], rendering a suboptimal binding condition for apoptosis
detection in vivo. In addition, excessive uptake by the liver
and the kidney further limits the application of native ANV
for in vivo apoptosis imaging [9]. In light of these drawbacks
of native ANV concerning the in vivo detection of apoptosis,
the development of derivatives of ANV with an improved
binding proﬁle to PS and pharmacokinetic properties has
been under intensive investigation recently.
ANV possesses anticoagulant and antithrombotic activ-
ity by forming 2-dimensional arrays on anionic mem-
brane surfaces, and thus making the anionic phospholipids
unavailable for assembly of coagulation enzyme complexes
[10]. In attempts to developing potent thrombogenesis
inhibitors, a series of recombinant anticoagulant fusion
proteins, consisting of an ANV moiety and a Kunitz protease
inhibitor (KPI) domain that binds to various coagulation
factors with high aﬃnity and speciﬁcity, were reported
recently [11]. One of these constructs, ANV-6L15, was found
to possess a higher binding aﬃnity to PS compared to native
ANV at physiological Ca2+ concentrations; the apparent
dissociation constant for ANV-6L15 binding to erythrocyte
ghosts was approximately 4-fold lower than that of ANV
at 1.2–2.5mM Ca2+ [12]. The previous study reveals that
ANV-6L15 may provide improved detection of PS exposed
onthemembranesurfacesofpathologicalcellsinvitroandin
vivo. The present study investigates the use of radioiodinated
ANV-6L15 as an imaging agent for apoptosis detection.
2.MaterialsandMethods
2.1. Materials and Reagents. 123I-NH4Iw a sp r o d u c e db y
a compact cyclotron (Ebco TR30/15, Vancouver, Canada)
at the Institute of Nuclear Energy Research (INER, Long-
tan, Taoyuan, Taiwan). 125I-NaI was supplied by IZO-
TOP Institute of Isotopes (Budapest, Hungary). Iodogen
(1,3,4,6-tetrachloro-3,6-diphenylglycoluril) precoated iodi-
nation tubes were purchased from Pierce Biotechnology
(Rockford, IL, USA). ANV-6L15 was produced by expression
in Escherichia coli as described previously [9]. ANV and
FITC-ANV apoptosis detection kit were obtained from
Becton Dickinson (Franklin Lakes, NJ, USA). Nanosep 10K
Centrifugal Devices were purchased from Pall Life Science
(Ann Arbor, MI, USA). Stabilized 5C Cell Control was a
generous gift from Beckman Coulter (Fullerton, CA, USA).
Camptothecin (CPT) was purchased from Sigma (Cam-
bridge, MA, USA). Acute lymphoblastic cell line of human
Jurkat T-cell was obtained from Bioresource Collection and
Research Center (Hsinchu, Taiwan). Cell culture materials
were obtained from Gibco BRL (Grand Island, NY, USA).
All other chemicals were purchased from Merck (Darmstadt,
Germany).
2.2. Radioiodination of ANV and ANV-6L15. The Iodogen
method [13, 14] was adopted for radiolabeling of ANV
and ANV-6L15 with 123Io r125I. Brieﬂy, ten μgo fA N V
and ANV-6L15 were dissolved in 15μLo f0 . 1 MK H 2PO4
(pH 8) solution and reacted with radioiodide (370MBq
123I-NH4I or 185MBq 125I-NaI) in a tube precoated with
50μg of Iodogen. After gentle agitation of the tube at room
temperature for 10min, the reaction mixture and the rinse
of the tube (with 400μL0 . 0 1 MK H 2PO4 solution, pH
7.4) were loaded on a Nanosep 10K Centrifugal Device
prewashed with 400μL0 . 0 1MK H 2PO4 solution (pH 7.4).
After centrifugation of the Nanosep tube at 15,000×gf o r
5min and washing twice with 400μL0 . 0 1MK H 2PO4 (pH
7.4) solution, the radioiodinated protein on the membrane
of Nanosep tube was harvested.
2.3. Radiochemical Analysis by High-Pressure Liquid Chro-
matography. The radiochemical purities of radioiodinated
ANV and ANV-6L15 were determined on an analytical
HPLC system (Waters 600E, Milford, MA, USA) equipped
with a size-exclusion column (Waters Ultrahydrogel 250
column, 7.8 × 300mm, 6μm) and a Waters Ultrahydrogel
guard column (6.0mm × 40mm, 6μm). After loading
10μL of diluted radiolabeled protein, the column was eluted
with 0.01M KH2PO4 solution (pH 7.4) at a ﬂow rate of
0.8mL/min. The radioactivity of the eluate was monitored
online by a ﬂow detector (FC-1000, Bioscan, Washington,
DC, USA).
2.4. Erythrocyte Ghost Binding Assay. Stabilized erythrocyte
ghosts were prepared by hypotonic treatment of 5C Cell
Control (Beckman Coulter) to expose more PS sites. The
cell control erythrocytes were incubated alternatively with
water and 10mM HEPES buﬀer (containing 137mM
NaCl, 4mM KCl, 0.5mM MgCl2,0 . 5m MN a H 2PO4,0 . 1 %
D-glucose, and 0.1% BSA; pH 7.4) twice at 37◦Cf o r
45min. Following centrifugation at 16,000×g for 5min, the
pellet of stabilized erythrocytes was resuspended in 10mM
HEPES buﬀer. For the binding studies, erythrocyte ghosts
(1.1 × 109 cells/mL) were incubated with 125I-ANV and
125I-ANV-6L15, respectively, in binding buﬀers (10mM
HEPES buﬀer, pH 7.4, with 1.2–10mM calcium chloride
solution) at room temperature for 30min. Bound and
free radioiodinated proteins were then separated by
centrifugation at 16,000×g for 10min. The radioactivities
in the pellet and the supernatants were measured using
an automatic gamma counter (Wizard 1470, PerkinElmer
Wallac, Turku, Finland), and the percentage of radioactivity
bound to erythrocyte ghosts was calculated. Binding of
125I-NaI to erythrocyte ghosts served as a negative control.
2.5. Apoptotic Cell Binding Assay. Apoptotic Jurkat T-cells
were prepared by treatment with an anticancer drug camp-
tothecin (CPT; 8μM) for 24 hours [15, 16]. In brief, cell
culture ﬂasks with RPMI 1640 medium (5mL containing
107 cells) mixed with CPT-DMSO solution (5μL; 8mM)
and DMSO (5μL) served as CPT-treated and vehicle-
treated groups, respectively. Apoptosis of Jurkat T-cells wasJournal of Biomedicine and Biotechnology 3
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Figure 1: Representative HPLC radiochromatograms of (a) 123I-ANV and (b) 123I-ANV-6L15. HPLC analysis was performed on a Waters
Ultrahydrogel 250 column, (7.8×300mm, 6μm) guarded with a Waters Ultrahydrogel guard column (6.0mm × 40mm, 6μm), with mobile
phase of isocratic 0.01M KH2PO4 solution (pH 7.4) at a ﬂow rate of 0.8mL/min.
conﬁrmed by ﬂow cytometry using FITC-ANV and pro-
pidium iodide (PI) staining. Apoptotic cells were identiﬁed
as ANV+PI− and live cells as ANV−PI− on a FACScan
analyzer (Becton, Dickinson and Company, CA, USA). For
binding assay, untreated (neither CPT-DMSO nor DMSO
mixed), vehicle-treated and CPT-treated Jurkat T-cells were
incubated with approximately 66.6MBq 123I-ANV, 123I-
ANV-6L15, or 123I-NH4I, respectively, in 0.5mL binding
buﬀer (10mM HEPES, 137mM NaCl, 4mM KCl, 0.5mM
MgCl2,0 . 5m MN a H 2PO4, 0.1% glucose, 0.1% BSA, 1.2mM
CaCl2,p H7 . 4 )a tr o o mt e m p e r a t u r ef o r1 5 m i n .T h ec e l l s
were pelleted, washed once with the binding buﬀer, and
resuspended in the same buﬀer. The radioactivity bound to
the cells was measured using an automatic gamma counter
(Wallac 1470 Wizard).
2.6. Biodistribution and Imaging of Radioiodinated ANV-
6L15. All animal experiments were approved by the Institu-
tional Animal Care and Use Committee (IACUC) of INER.
All animals were kept in a temperature-controlled room (at
22.5 ± 2◦C) with illumination cycle of 12 hours per day and
were maintained on a standard diet (Lab diet; PMI Feeds, St.
Louis, MO, USA) with free access to tap water.
For biodistribution study, 18 eight-week-old male
BALB/c mice (obtained from the National Animal Center,
Taipei,Taiwan) wereinjected intravenously viathelateraltail
vein with 444 ± 37kBq 123I-ANV-6L15 and sacriﬁced at 2,
10, 30, 60, 120, and 180min after injection (three mice for
each time point) under isoﬂurane anesthesia. Blockade of
speciﬁc uptake of free iodide was achieved by intraperitoneal
injection of KI (3.9mg per mouse) 30min before radiotracer
injection. At the selected time, main organs and tissues were
obtained, weighed, and counted for radioactivity on a Wallac
1470 gamma counter. The distribution data were expressed
as percentage of the injected dose per organ (%ID/organ)
and per gram of tissue (%ID/g).
For in vivo imaging study, one BALB/c mouse was
injected via tail vein with 18.5MBq of 123I-ANV-6L15 in
physiological saline (100μL). Under isoﬂurane anesthesia,
whole body scans were acquired on an X-SPECT (Gamma
Medica, Northridge, CA, USA) equipped with an HRES
Table 1: Labeling yields and radiochemical purities of radioiodi-
nated ANV and radioiodinated ANV-6L15.
Labeling yield
(%)
Radiochemical purity
(%)
123I-ANV 51.4 ± 8.4 96.0 ± 3.9 (n = 7)
123I-ANV-6L15 44.2 ± 4.9 98.0 ± 2.6 (n = 6)
125I-ANV 74.0 ± 6.6 97.6 ± 1.0 (n = 4)
125I-ANV-6L15 74.5 ± 7.3 96.1 ± 1.4 (n = 4)
Data expressed as mean ± SD.
(high resolution electronic system) collimator 60–210min
after injection.
2.7. Statistical Analysis. Data were expressed as mean ±
standard deviation (SD). The binding of 123I-ANV and 123I-
ANV-6L15 in CPT-treated Jurkat T-cells were compared
using Student’s t-test, with P<. 05 indicating statistical
signiﬁcance.
3. Results and Discussion
3.1. Radiochemical Proﬁle of Radioiodinated Proteins. ANV-
6L15 as well as native ANV were successfully labeled with
radioiodine using Iodogen method. The representative size-
exclusion chromatograms of radioiodinated ANV and ANV-
6L15 were shown in Figure 1. The retention times of radioio-
dinated ANV, ANV-6L15, and radioiodide were 8.33 ±
0.07min, 9.20 ± 0.15min, and 15.5 ± 0.25min, respectively.
Since the molecular weight of ANV-6L15 (contains 378
amino acids) is larger than that of ANV (contains 319 amino
acids), the slightly longer retention time of radioiodinated
ANV-6L15 compared to that of 123I-ANV possibly reﬂected
the diﬀerence in molecular conformation and/or interaction
withthechromatographicmediumratherthanthediﬀerence
in molecular size. The labeling yields of 123I-ANV, 123I-
ANV-6L15, 125I-ANV, and 125I-ANV-6L15 were 51.4 ± 8.4%,
44.2 ± 4.9%, 74.0 ± 6.6%, and 74.5 ± 7.3%, respectively.
The radiochemical purities of 123I-ANV, 123I-ANV-6L15,
125I-ANV, and 125I-ANV-6L15 were 96.0 ± 3.9%, 98.0 ±
2.6%, 97.6 ± 1.0%, and 96.1 ± 1.4%, respectively (Table 1).4 Journal of Biomedicine and Biotechnology
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Figure 2: Binding of 125I-ANV and 125I-ANV-6L15 to erythrocyte ghosts. (a) Time course of binding of 125I-ANV or 125I-ANV-6L15 to ghost
erythrocytes in the presence of 2.5mM Ca2+ at room temperature. (b) Binding of 125I-ANV or 125I-ANV-6L15 to ghost erythrocytes under
various concentrations of Ca2+. Data are expressed as mean ± SD of three independent experiments.
Theradioiodinatedproteinswerestableatroomtemperature
f o ru pt o1 0h o u r s( d a t an o ts h o w n ) .
Themostcommonlyusedtechniquesforradioiodination
of proteins are Iodogen, Iodobead and chloramine-T meth-
ods. Previously reported labeling yields of radioiodinated
ANV using Iodogen and Iodobead were 70% and 40%,
respectively[13,14,17].Thelabelingyieldsofradioiodinated
ANV and ANV-6L15 in this study were comparable with the
data reported in the literature.
Due to limited availability of 123I, we used 123I mainly
for animal studies (biodistribution and SPECT imaging)
and related Jurkat T-cell binding assay. To prevent frequent
shortage of 123I during the course of study, we used relatively
longer half-lived and commercially available 125If o ri nv i t r o
study on erythrocyte ghost cell. We assume similar binding
characteristics between radiolabels of 123Ia n d125I.
3.2. Erythrocyte Ghost Binding Assay. To determine whether
ANV-6L15 maintained its biological activity after radioiodi-
nation, erythrocyte ghost binding assay was performed. The
results showed that the binding of 125I-ANV or 125I-ANV-
6L15 to erythrocyte ghosts was time- and Ca2+-dependent
(Figures 2(a) and 2(b)). Maximal binding of either 125I-
ANV or 125I-ANV-6L15 to erythrocyte ghosts occurred
after 30min incubation in the presence of 2.5mM Ca2+;
the binding ratio was 16.97 ± 0.66% and 35.07 ± 0.53%
for 125I-ANV and 125I-ANV-6L15, respectively (Figure 2(a)).
The binding of either radioiodinated protein to erythrocyte
ghosts steeply increased as Ca2+ concentration increased
from 1.2mM to 10mM, and the binding ratio reached 77.3
± 0.45% and 84.7 ± 0.26% for 125I-ANV and 125I-ANV-
6L15, respectively, at 10mM Ca2+ (Figure 2(b)). 125I-ANV-
6L15 exhibited higher binding ratios than 125I-ANV (Figures
2(a) and 2(b)). Thus, radioiodinated ANV-6L15 appeared
to possess a higher aﬃnity to membrane PS-binding sites
compared to radioiodinated ANV.
Lahorte et al. [13] reported that the optimal incubation
time for maximal platelet binding was 20min or longer in
the presence of 5mM Ca2+ and reached a plateau at 20mM
Ca2+ when incubated for 30min. Our data showed that the
maximal binding of either 125I-ANV or 125I-ANV-6L15 to
erythrocyte ghosts appeared at 30min in the presence of
2.5mM Ca2+ and reached a plateau at 8mM Ca2+ when
incubated for 30min.
The mechanism for the increased binding aﬃnity of
ANV-6L15 for erythrocyte membranes compared with
ANV is currently unknown. The coexpression of phos-
phatidylethanolamine (PE) on the erythrocyte membranes
was proposed to contribute importantly to the increased
aﬃnity of ANV-6L15 compared with ANV [12].
3.3. Apoptotic Cell Binding Assays. Figure 3 showed a typical
ﬂ o wc y t o m e t r i cd o tp l o tf o rt h eu n t r e a t e da n da p o p -
totic CPT-treated Jurkat T-cells. An increased proportion
of apoptotic (ANV+PI−) and necrotic (ANV+PI+)c e l l s
was observed in CPT-treated cells. The binding of 123I-
ANV-6L15 to CPT-treated cells (23.3 ± 2.1cpm/104 cells)
was signiﬁcantly higher than those of untreated- (8.2 ±
0.4cpm/104 cells) and vehicle- (DMSO-) treated Jurkat T-
cells (P<. 03; Figure 4). In contrast, the binding of 123I-ANV
(approximately 4cpm/104 cells) or 123I-iodide (<1cpm/10 4
cells) was far below those of 123I-ANV-6L15 among diﬀerent
groups, and no increase of 123I-ANV binding to apoptotic
Jurkat T-cells was observed (Figure 4). The lack of increased
123I-ANV binding to apoptotic Jurkat T-cells was possibly
due to relatively low binding aﬃnity of 123I-ANV for PS-
exposed membranes at the physiological concentration Ca2+
(1.2mM).Journal of Biomedicine and Biotechnology 5
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Figure 3: Representative ﬂow cytometric histograms of apoptotic Jurkat T-cells stained with annexin V-FITC and propidium iodide (PI).
Jurkat T-cells (2 × 106/mL) were left untreated or treated with camptothecin (CPT, 8μM) at 37◦C for 24h, followed by staining with ANV-
FITC and PI. Apoptotic cells were identiﬁed as ANV+PI− and live cells as ANV−PI− on an FACScan analyser.
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Figure 4: Binding of 123I-ANV and 123I-ANV-6L15 to apoptotic
Jurkat T-cells. Jurkat T-cells were either left untreated or treated
with camptothecin (CPT, 8μM) and/or vehicle (5μL DMSO).
3.4. Biodistribution and Imaging of Radioiodinated ANV-
6L15 in Mice. The biodistribution of 123I-ANV-6L15 in
BALB/c mice are depicted in Table 2. After bolus injec-
tion via tail vein (approximately 25ng protein/mouse),
123I-ANV-6L15 showed an initial rapid clearance from the
blood (40.01 ± 6.25% and 12.29 ± 1.22% ID/organ at
2min and 60min after injection, resp.). The liver had
the highest radioactivity (11.40 ± 1.34% ID/organ) at
2min after injection. The organ with the second highest
radioactivity was the kidneys (8.61 ± 0.35% ID/organ
at 10min after injection). 123I-ANV-6L15 fusion protein
did not cross the blood-brain barrier as indicated by the
low brain uptake (<0.5% ID/g in average). Low uptake
in the thyroid reﬂected low level of radioiodide dissoci-
ation from the radiolabeled protein in vivo. The slight
increase of thyroid uptake at 120 and 180min could be
due to in vivo 123I dissociation from the radiolabeled
protein.
As reported previously [3, 14], 123I-ANV was rapidly
cleared from the blood following a biexponential decay and
predominant uptake in the kidneys, liver, and gastrointesti-
naltract.Theresultofthisstudyrevealedthat 123I-ANV-6L15
also excreted via kidneys.
In vivo imaging of 123I-ANV-6L15 distribution in a
BALB/c mouse after bolus injection via tail vein (approx-
imately 1μg protein/mouse) showed high uptake of the
tracer in the liver and the kidneys (Figure 5). The uptake
of 123I-ANV-6L15 in these organs may limit the evaluation
of apoptosis in abdominal regions. Further studies of
biodistribution and SPECT imaging will be performed at
later time points. We will conduct dosimetry calculation
for 123I-ANV-6L15 and compare with 123I-ANV. The novel
tracerwillbeevaluatedinanimalmodelswithstress-induced
apoptosis in the future.6 Journal of Biomedicine and Biotechnology
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Figure 5: In vivo SPECT images of 123I-ANV-6L15 fusion protein in an eight-week-old male BALB/c mouse. 123I-ANV-6L15 (18.5MBq in
100μL physiological saline) was injected via tail vein of the mouse under isoﬂurane anesthesia. Whole body scan was acquired at 60–210min
after injection.
4. Conclusions
ANV-6L15 was successfully labeled with radioiodine using
Iodogen method. Radioiodinated ANV-6L15 showed signiﬁ-
cantly higher binding to PS-exposed erythrocyte ghosts and
camptothecin-inducedapoptoticJurkatT-cellsatphysiologi-
calconcentrationofCa2+ comparedtothatofradioiodinated
ANV in vitro. Biodistribution study showed that 123I-ANV-
6L15 was rapidly cleared from the blood. Further imaging
studies in animal models of apoptosis are warranted. Owing
to higher binding aﬃnity to PS, radioiodinated ANV-
6L15 could be more sensitive than radioiodinated ANV to
detect the apoptosis-associated treatment and human dis-
orders, such as radiation/chemotherapy eﬃcacy, myocardial
ischemia or infarct, infectious diseases, and neurodegen-
erative diseases. Taken together, these results suggest that
the radioiodinated ANV-6L15 may be a better scintigraphic
tracer for apoptosis detection compared with ANV.
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